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Degradation of the extracellular matrix components elastin and collagen has been implicated in vascular diseases,
including abdominal aortic aneurysm (AAA) and atherosclerotic plaque rupture. Increased expression of matrix
metalloproteinases (MMPs) is involved in these disease processes. Our previous studies have demonstrated that MMP-2
derived from mesenchymal cells is required for aneurysm development in a murine model. Doxycycline is a nonspecific
inhibitor of MMPs. In the present study, the mechanisms of the inhibitory effects of doxycycline on MMP-2 expression
from cultured human aortic smooth muscle cells (SMCs) and human aortic aneurysm tissue explants were studied.
Doxycycline inhibited MMP-2 expression from cultured SMCs in a concentration-dependent manner (5-40 g/mL;
inhibitory concentration of 50%, 6.5 g/mL). At normal therapeutic serum concentration (5 g/mL) doxycycline
significantly reduced MMP-2 production from SMCs (37%; P < .05), which were stimulated with conditioned media
from macrophage or lymphocyte co-culture simulating the inflammatory milieu of AAA tissue. This correlated with a
decrease in MMP-2 mRNA half-life, from 49 hours to 28 hours, which suggests that doxycycline inhibits SMC MMP-2
production in part by reducing MMP-2 mRNA stability. When AAA tissue was cultured for 10 days with doxycycline at
concentrations of 2.5 to 40 g/mL, the media exhibited a concentration-dependent decrease in both active and latent
forms of MMP-2 and MMP-9. Doxycycline at a concentration of 5 g/mL reduced active and latent MMP-2 secreted
from cultured AAA tissue by 50% and 30%, respectively (P < .05). These study findings demonstrate that doxycycline at
standard therapeutic serum concentrations inhibits MMP-2 expression from cultured human aortic SMCs and AAA
tissue explants. Inasmuch as MMP activity contributes to extracellular matrix degradation in AAAs and atherosclerotic
plaque, doxycycline may have potential value in treating these diseases. (J Vasc Surg 2003;38:1376-83.)
Clinical Relevance: Numerous studies have made it clear that proteolytic degradation of aortic structural proteins is
responsible for initiation and expansion of abdominal aortic aneurysm (AAA). Elastin and collagen degradation in
aneurysm tissue is caused, in part, by MMP-2 produced by mesenchymal cells of the aortic media. The present study shows
that the antibiotic doxycycline can inhibit MMP-2 in cell culture and in human aneurysm tissue ex vivo. This lends further
support to the concept that doxycycline could inhibit AAA growth. Presently there is no medical treatment to inhibit
AAA growth, and the only effective option to protect against rupture is repair. A medical option, if it existed, could lead
to screening, detection, and medical treatment of small aneurysms.
Abdominal aortic aneurysm (AAA) is common in the
US elderly population. Its most significant complication,
rupture of the aorta, is responsible for more than 15,000
deaths annually in the United States.1 The only proven
treatment is mechanical repair of large aneurysms. Destruc-
tion of extracellular matrix components of the artery, in-
cluding elastin and fibrillar collagen, is a consistent feature
of AAA,2-4 and is associated with dense inflammatory infil-
tration of the media and adventitia, consisting of macro-
phages and lymphocytes.5,6
The matrix metalloproteinases (MMPs), a family of
zinc endopeptidases, are responsible for degradation of
extracellular matrix in AAAs.3,7,8 Among MMPs identified
in AAA tissue, MMP-2 (gelatinase A) is able to degrade
both major macromolecules of aortic extracellular matrix,
elastin and fibrillar collagen.9,10 MMP-2 is predominantly
expressed by mesenchymal cells, that is, smooth muscle
cells (SMCs) and fibroblasts.11 Increased MMP-2 protein
and messenger RNA levels have been reported in AAAs,
which suggests a role in pathogenesis or progression of
aneurysms.12-14 Our data demonstrate that MMP-2 from
mesenchymal cells is required for aneurysm formation.15
Of importance, MMP-2 expression appears to be increased
when mesenchymal cells are surrounded by inflammatory
cells.14,16 We have confirmed with in vitro studies that
MMP-2 expression in aortic SMCs is increased when cells
are incubated with media conditioned by exposure to mac-
rophages and lymphocytes.17
Drugs that block MMP expression from vascular mes-
enchymal cells could have therapeutic potential in treating
AAA. Independent of its antimicrobial properties, doxycy-
cline, a derivative of tetracycline, is a nonspecific MMP
inhibitor.18 Doxycycline inhibits MMP-2 secretion from
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cultured epithelial cells19; however, the mechanism of this
inhibition is not understood. Petrinec et al20 and Pyo et al21
showed that doxycycline inhibits aneurysm formation in an
elastase-induced rat model of AAA. Both MMP-2 and
MMP-9 expression appear to be reduced in this model.20
Our previous findings demonstrate that standard doxycy-
cline doses inhibit AAA growth in a mouse model and that
this occurs with decreased MMP activity.22 Although these
animal studies suggest that doxycycline could have a role in
treatment of AAA, they raise several important questions.
Will doxycycline inhibit MMP-2 production by human
aortic SMCs or in human AAA tissue? What is the mecha-
nism of this inhibition? Can MMP-2 inhibition be achieved
within the standard therapeutic dose range for doxycycline?
The purpose of the present study was to investigate the
effects and mechanisms of doxycycline on MMP-2 expres-
sion in cultured aortic SMCs and human AAA tissue ex-
plants.
METHODS
Cell culture and treatment. Human SMC culture
was established from normal infrarenal aorta obtained from
transplant donors, as described.22 SMCs between the sec-
ond and fourth passage were used for the experiments.
Monocytes and lymphocytes (a generous gift from Dr
Howard E. Gendelman, Department of Pathology and
Microbiology, University of Nebraska Medical Center)
were separated and purified with countercurrent centrifugal
elutriation of peripheral blood mononuclear cells from
leukophoresis in healthy donors. The purity (97%) of the
monocytes was confirmed with the criteria for cell anatomy
on Wright-stained cytosmears, and with granular peroxi-
dase and nonspecific esterase staining. The monocytes (3
106) were cultured for 7 days with Dulbecco modified
Eagle medium (DMEM; Gibco BRL, Gaithersburg, Md)
containing 10% human serum (Sigma, St Louis, Mo) and
2-g/mL purified recombinant human macrophage colo-
ny-stimulating factor (Genetics Institute, Cambridge,
Mass), to enable differentiation into macrophages. Periph-
eral lymphocytes were activated with phytohemagglutinin
(1 g/mL; Sigma) for 24 hours. Co-culture was carried
out by incubation of 3.0 107 macrophages and 1.8 108
activated lymphocytes in 30 mL of serum-free M-199
medium. The conditioned medium was collected after 24
hours. Gelatin-binding proteins, including MMP-2 and
MMP-9 present in the conditioned medium of co-cultured
inflammatory cells, were removed with gelatin-sepharose
(Pharmacia Biotech, Uppsala, Sweden) before the medium
was applied to SMCs. Zymography was performed on the
conditioned medium after the gelatin-sepharose column to
confirm the absence of MMP-2 and MMP-9. SMCs in
serum-free M-199 or SMCs activated with the conditioned
medium of macrophage-lymphocyte co-culture were then
treated with doxycycline (Sigma) at concentrations of 5 to
40 g/mL for 24 hours. The SMC medium was harvested,
and total RNA was extracted from the cells.
AAA tissue culture and treatment. Infrarenal aortic
tissues were obtained at surgical repair of AAA. Informed
consent was obtained for tissue collection in accordance
with a protocol approved by the Institutional Review Board
and Research Committee of the University of Nebraska
Medical Center and the Omaha Veterans Administration
Medical Center. The AAA tissue was cut into pieces 10 mm
in diameter and incubated in a 12-well plate with serum-
free M-199 medium. Doxycycline at concentrations of 2.5
to 40 g/mL was added to the culture. The culture me-
dium was changed every 24 hours. The tissue culture
medium was collected at day 10 for MMP analysis.
Gelatin zymography. MMP-2 and MMP-9 concen-
trations in culture media (10 L per lane) were measured
with gelatin zymography, which was conducted with so-
dium dodecylsulphate polyacrylamide gel electrophoresis
(SDS-PAGE) containing gelatin (0.8 mg/mL), as de-
scribed.15 Conditioned media from human macrophages
and fibroblasts served as a positive control for MMP-9 and
MMP-2, respectively. Gelatinolytic activities were quanti-
fied with densitometry (Molecular Dynamics, Piscataway,
NJ).
Western blot analysis. Media from tissue culture (70
L per lane) were subjected to 10% SDS-PAGE under
reducing conditions, and the proteins were transferred to
0.45 mol/L nitrocellulose membranes (BioRad, Her-
cules, Calif). The membrane was immunoblotted with
mouse anti-human MMP-2 primary antibody (Oncogene,
Cambridge, Mass), and the secondary sheep anti-mouse
immunoglobulin G was conjugated with horseradish per-
oxidase (Amersham Corp, Arlington Heights, Ill). The
specific MMP-2 bands were detected with the electro-
chemiluminescent system (Amersham) and quantified with
densitometry.
MMP-2 mRNA half-life determination. The half-
life of MMP-2 mRNA in SMCs was measured in serum-free
M-199 control cultures and cultures containing 10g/mL
of doxycycline. After doxycycline treatment for 24 hours,
actinomycin D (5 g/mL; Sigma) was added to the cul-
tures. Then the total RNA was extracted from SMCs at 0, 4,
8, 12, 24, and 48 hours after addition of actinomycin D.
MMP-2 mRNA was analyzed with dot-blot hybridization.
Total RNA (5 g) was mixed with 20 L of 100% form-
amide, 7 L of 37% formaldehyde, and 2 L of 20
saline–sodium citrate (SSC), and denatured by heating at
65°C for 15 minutes. The samples were placed on ice, and
80L of 20 SSC were added to each sample. The samples
were then blotted onto Nytran membrane (Schleicher and
Schuell, Keene, NH) and washed with 1 mL of 10 SSC,
and the RNA was immobilized on the membrane with
ultraviolet illumination. Hybridization with phosphate 32–
labeled MMP-2 complementary DNA probe, washing, and
autoradiography of dot-blot membrane were performed.
Northern blot analysis. Total RNA was extracted
with TRIzol reagent (Gibco BRL), and 2 g of RNA were
electrophoresed on a 1.4% agarose/2.2-mmol/L formal-
dehyde gel. RNA was transferred onto Nytran membranes
with capillary elution. The membranes were hybridized
with 32P random-labeled cDNA probes overnight at 55°C
in a solution containing 50% formamide, 5 SSC, 5
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Denhardt solution, 1% SDS, and 250-g/mL sheared
salmon sperm DNA. The membranes were washed three
times in 2 SSC at room temperature, followed by three
30-minute incubations in 0.1 SSC and 0.5% SDS at
65°C. The hybridized signals were visualized with autora-
diography with Kodak x-ray film, and were quantified with
densitometry.
Cell proliferation assay. Equal numbers of SMCs
(3000 cells per well) were cultured in 96-well plates with
serum-free M-199 and various concentrations (5-40 g/
mL) of doxycycline for 24 hours. The cell numbers were
then evaluated with the 3-(4,4-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction assay with
a Cell Titer 96 kit (Promega, Madison, Wis), which mea-
sures conversion of tetrazolium salt into blue formazan by
viable cells. Absorbance of soluble MTT formazan products
was measured at 490 nm.
Statistical analysis. The results are presented as mean
 SEM. Differences between groups were determined with
analysis of variance. P  .05 was considered significant.
Results of mRNA half-life were compared with the Student
t test for equality of slopes. Correlation was determined
with liner regression, and expressed as correlation
coefficient.
RESULTS
Doxycycline inhibits SMC MMP-2 production. To
assess the effect of doxycycline on expression of MMP-2 by
SMCs, we performed gelatin zymography and Western blot
analysis. Only the latent form of MMP-2 was detected in
both assays (Fig 1, A, B). When stimulated with co-cul-
tured macrophage or lymphocyte conditioned medium,
SMCs produced two to three times more MMP-2 than
unstimulated cells did (Fig 1, C). Doxycycline inhibited
MMP-2 secretion from both conditioned media stimulated
and unstimulated SMCs in a concentration-sensitive re-
sponse (Fig 1, A). In conditioned medium stimulated cells,
the MMP-2 concentration was decreased by 37% with 5
g/mL of doxycycline, by 80% with 10 g/mL, and by
97% with 20 g/mL of doxycycline. Inhibition of MMP-2
production by doxycycline was more substantial when the
cells were incubated with co-cultured macrophage or lym-
phocyte conditioned medium (Fig 1, C). Inasmuch as
serum doxycycline levels measured in volunteers given a
standard dose (2-3 mg/kg/d) of doxycycline were in the
range of 2 to 6 g/mL,22 we specifically compared inhibi-
tion of MMP-2 production in SMCs incubated with and
without conditioned media at 5 g/mL of doxycycline. At
a concentration of 5 g/mL, doxycycline significantly de-
creased MMP-2 production in SMCs incubated with mac-
rophage or lymphocyte co-cultured condition media (P 
.05); however, decrease in unstimulated SMCs was not
statistically significant (Fig 1, D). These observations sug-
gest that doxycycline has a selective effect in inhibiting
MMP-2 overexpression.
Doxycycline does not affect cultured aortic SMC
viability. It was important to demonstrate that the effects
of doxycycline on MMP activity are not the result of drug
cytotoxicity. This was addressed by determining cell num-
bers in the presence of doxycycline. The number of cells at
Fig 1. Effect of doxycycline on matrix metalloproteinase-2
(MMP-2) production from cultured aortic smooth muscle cells
(SMCs). Aortic SMCs cultured in either serum-free M-199 (Control)
or macrophage or lymphocyte co-culture medium (Stimulated) were
treated with doxycycline at indicated concentrations for 24 hours.
MMP-2 concentration in cell culture medium at indicated doses of
doxycycline were determined with gelatin zymography (A) and West-
ern blot analysis (B). C, MMP-2 band intensity was determined with
quantitative densitometry. Quantitative values in arbitrary integrator
units represent mean obtained from three independent experiments.
D, Inhibition of MMP-2 production from SMCs treated without
(Control) or with (Stimulated) co-cultured macrophage or lympho-
cyte media in response to 5 g/mL of doxycycline. Gelatin zymog-
raphy (lower panel) represents SMCs from three separate plates. *P
.05 compared with control SMCs; # P .05 compared with medium-
treated SMCs without doxycycline.
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indicated concentrations of doxycycline was tested with the
MTT reduction assay (Fig 2). There was no significant
change in cell number when SMCs were treated with
doxycycline at 5 to 40 g/mL for 24 hours. This suggests
that the inhibitory effect of doxycycline on MMP activity is
not due to cytotoxicity of this drug.
Doxycycline reduces MMP-2 mRNA stability in
SMCs. A decrease in steady-state levels of MMP-2 mRNA
was observed at Northern blot analysis after SMCs were
treated with doxycycline at therapeutic concentrations (5
and 10 g/mL) for 24 hours (Fig 3, A). This finding was
observed on three separate Northern blots from different
plates. This did not represent a general decrease in cellular
mRNA, because glyceraldehyde-3-phosphate dehydroge-
nase mRNA was unchanged. At concentrations of doxycy-
cline greater than 10 g/mL, no consistent downregula-
tion of mRNA was observed. To determine whether
doxycycline can regulate expression of MMP-2, the nuclear
run-on transcription assay was performed. Doxycycline did
not appear to change SMC MMP-2 mRNA transcription
rate (data not shown). To investigate whether doxycycline
can affect transcription of MMP-2 in SMCs, stability of
MMP-2 mRNA in SMCs was measured with dot-blot
hybridization. After addition of the gene transcription in-
hibitor actinomycin D, decrease in concentration of
MMP-2 mRNA was measured with and without doxycy-
cline treatment. In control SMCs, the half-life of MMP-2
mRNA was estimated to be about 49 hours, consistent with
published observations.23 After doxycycline treatment,
MMP-2 mRNA half-life was reduced to about 28 hours.
Furthermore, the slopes of mRNA half-life data were sig-
nificantly different between control and doxycycline-
treated SMCs (P  .002; Fig 3, B), indicating that in-
creased degradation or reduced stability of MMP-2 mRNA
contributed to some of the observed doxycycline inhibition
of MMP-2 production in SMCs.
Doxycycline decreases MMP-2 and MMP-9 pro-
duction in AAA. To further test the efficacy and kinetic
features of doxycycline in AAA, we used explant cultures
from AAA tissue treated with doxycycline. At gelatin zy-
mography, both the latent and active forms of MMP-2 and
MMP-9 were observed in conditioned media–cultured
AAA tissue (Fig 4, A). Doxycycline at concentrations of 2.5
to 40 g/mL exhibited concentration-dependent inhibi-
tion of both latent and active MMP-2 and MMP-9 in AAA
tissue media collected at day 10 of tissue culture (Fig 4).
Linear regression analysis demonstrated a significant corre-
lation between increased doxycycline concentrations in tis-
Fig 2. Effect of doxycycline on proliferation of cultured aortic
smooth muscles (SMCs). SMCs were treated with indicated dose
of doxycycline in serum-free M-199 medium for 24 hours. Cell
numbers were determined by measuring conversion of tetrazolium
salt into blur formazan in viable cells. Values are mean  SE of
triplicate measurements. OD, Optic density.
Fig 3. Effect of doxycycline on steady-state level and stability of
matrix metalloproteinase-2 (MMP-2) mRNA from smooth muscle
cells. A, Aortic SMCs were treated with doxycycline at concentra-
tions of 5 and 10 g/mL for 24 hours. Total RNA was extracted
from the cells, and MMP-2 and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) mRNA was determined with Northern
blot analysis. B, Confluent cultures of human SMCs were incu-
bated in presence or absence of 20g/mL of doxycycline. After 24
hours, actinomycin D (5 g/mL) was added (0 h), and cultures
were further incubated for indicated times. Each value represents
results from three separate plates. Total RNA was extracted, dot
blotted onto Nytran membrane, and probed with [32P]deoxyciti-
dine triphosphate–labeled MMP-2 complementary DNA frag-
ment. Dot blots were quantified with densitometry, and data were
semilogarithmic plotted as mean SE (n 5). Best-fit curves were
generated and used to estimated messenger RNA half-life.
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sue culture and reduction of MMP-2 (r  0.91, P  .05)
and MMP-9 (r 0.82, P .05) activity in AAA tissue (Fig
4, B, C). Reduction of MMP-2 concentration in the me-
dium of AAA tissue explants treated with doxycycline was
corroborated with decreased MMP-2 protein content mea-
sured with Western blot analysis (Fig 4, D). The magnitude
of the decrease in MMP-2 activity from AAA tissues treated
with 5 g/mL of doxycycline was further quantified. At 5
g/mL, doxycycline significantly inhibited latent (30%)
and active (50%) MMP-2 from cultured AAA tissue (Fig 5).
DISCUSSION
Destruction of extracellular matrix components and
marked local inflammatory cell infiltration are striking his-
tologic features of human AAA tissue.5,24-26 Increased
local production of MMPs has been implicated in aortic
dilatation and AAA formation.4,7,11,14,27-30 It has also
been suggested that MMPs are important in weakening of
the atherosclerotic plaques in atherosclerosis disease,8,31-33
which leads to plaque rupture and acute myocardial
infarction.34 Drugs with ability to block MMP overex-
pression could have therapeutic potential in treating
these common and lethal diseases. Tetracyclines have
been used in the treatment of several chronic inflamma-
tory diseases associated with matrix destruction, such as
rheumatoid arthritis and periodontal disease.18,35,36
Their efficacy is presumed related to inhibiting local
MMP production.18 Inhibition of MMPs with doxycy-
cline,20 hydroxamate inhibitors such as BB-94,37 and
local overexpression of tissue inhibitor of MMP38 reduce
elastin destruction and aortic dilation in various animal
models of aneurysm. Among these therapeutic ap-
proaches, doxycycline is the most attractive for use in
patients with AAA, because of extensive clinical experi-
ence with this drug, and its relative safety profile.39
Fig 4. Doxycycline-inhibited matrix metalloproteinase (MMP)–9 and MMP-2 expression from cultured human
abdominal aortic aneurysm (AAA) tissue. Human AAA tissue was cultured in serum-free M-199 medium and treated
without or with doxycycline at 2.5 to 40 g/mL for 10 days. Media were collected, and MMP-2 and MMP-9
concentration was examined with gelatin zymography and Western blot analysis. A, Representative gelatin zymography
shows both MMP-2 and MMP-9 concentrations in media of AAA tissue culture treated at indicated dose of
doxycycline. MMP-9 (B) and MMP-2 (C) activity was quantified with densitometry. Values in arbitrary integrator units
were reported. D, Western blot analysis of MMP-2 concentration in culture media of AAA tissue treated with indicated
concentration of doxycycline.
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In the present study, doxycycline at concentrations of 5
to 40 g/mL directly inhibited MMP-2 production from
cultured human aortic SMCs and explanted AAA tissue.
MMP-2 is expressed by medial SMCs and adventitial fibro-
blasts in the aorta.11,14 In addition to its potent elastolytic
activity, MMP-2 also degrades intact fibrillar collagen and
gelatin.9 Increased MMP-2 protein and mRNA in AAAs
has been reported,12-14 indicating that MMP-2 may have a
critical role in aneurysm formation and dilation. Increased
expression of MMP-2 in AAAs was also suggested by
immunohistochemistry.11,14 These inflammatory cells con-
tribute directly to local production of MMP-9 and MMP-
12.7,15,40 With in vitro experimental conditions designed
to simulate the inflammatory milieu of AAA tissue, Grange
et al17 found that media conditioned from co-cultured
macrophages and phytohemagglutin-activated lympho-
cytes could upregulate MMP-2 expression from cultured
human aortic SMCs. This observation is consistent with
increased expression of MMP-2 from aortic mesenchymal
cells surrounded by infiltrated inflammatory cells14 and our
current observation of increased MMP-2 expression from
SMC cultured in the presence of macrophage or lympho-
cyte conditioned media. Inasmuch as cells were not
counted after 24-hour exposure to conditioned media, it is
possible, but unlikely, that the increased MMP-2 levels
reflect significant SMC proliferation. Interestingly, we
found that doxycycline has greater inhibitory effect when
MMP-2 production is stimulated by macrophage- or lym-
phocyte-conditioned media. We emphasize a dose of 5
g/mL because we found that serum doxycycline levels
measured in volunteers given a standard dose (2-3 mg/
kg/d) ranged from 2 to 6 g/mL.22 Doxycycline at 5
g/mL resulted in a significant 37% decrease in MMP-2
secretion from SMCs cultured in macrophage or lympho-
cyte conditioned media. The decrease in MMP-2 produc-
tion was only 15% when cells were cultured in serum-free
M-199 media. This suggests that doxycycline exhibits a
selective benefit by inhibiting MMP overproduction.
Doxycycline did not demonstrate toxic effects on cultured
SMCs at 5 to 40 g/mL after 24 hours, as determined by
the MTT assay, which estimates cell numbers.
An important finding is that doxycycline directly inhib-
its both latent and active MMP-2 secretion from explanted
human AAA tissue. We also noted decreased secretion of
MMP-9. With treatment of explant for 10 days, we did not
observe cytotoxicity, but did not directly measure cell via-
bility at the end of treatment. These findings corroborate
the animal work of Petrinec et al,20 who found that doxy-
cycline at very high doses inhibits development in an elas-
tase-induced rat AAA model in association with decreased
MMP-2 and MMP-9 production. Boyle et al41 showed that
doxycycline inhibited progressive elastin degradation in
porcine aorta explants. This correlates with decreased ex-
pression of MMP-2 and MMP-9. Doxycycline inhibits
murine AAA in associated with decreased MMP produc-
tion. Our finding that doxycycline at normal serum con-
centrations inhibits MMP-2 and MMP-9 expression from
explanted human AAA tissue is consistent with observa-
tions of Curci et al,42 who found that a short preoperative
course of doxycycline decreased AAA tissue MMP levels.
These studies suggest that doxycycline may be effective in
clinical trials designed to inhibit growth of small AAAs.
The mechanism of inhibition of MMP production by
tetracyclines has not been clearly defined. This ability of
doxycycline is functionally independent of its antibiotic
properties.18 Direct inhibition of MMPs by binding to
metal ions such as Ca2 and Zn2 is seen at concentrations
of doxycycline well above expected serum concentrations
(50 g/mL).43 Uitto et al19 reported that doxycycline
downregulates MMP-2 mRNA in cultured epithelial cells.
Jonat et al44 reported downregulation of MMP-3 gene
transcription with tetracycline from skin fibroblasts. We
investigated whether doxycycline alters transcriptional reg-
ulation of MMP-2, and found that this does not appear to
be so. However, we observed significantly decreased
MMP-2 mRNA half-life and steady-state of MMP-2
mRNA when SMCs were treated with doxycycline. To our
knowledge, ours is the first report of regulation of MMP-2
production involving posttranscriptional destabilization of
MMP-2 mRNA. This effect may be beneficial in treating
AAA.
In summary, at normal serum concentrations doxycy-
cline can directly inhibit MMP-2 expression from cultured
Fig 5. Effect of therapeutic dose of doxycycline on matrix metal-
loproteinase-2 (MMP-2) expression from cultured AAA tissue.
Explanted AAA tissue was treated with 5 g/mL of doxycycline
for 10 days. MMP-2 concentration in tissue culture medium was
determined with gelatin zymography, and quantified with densi-
tometry. Values represent mean  SE of three different patient
samples run in triplicate. *P  .05; **P  .01. Gelatin zymogra-
phy (lower panel) represents a patient sample run in triplicate.
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SMCs and MMP-2 and MMP-9 production in human
AAA. Downregulation of MMP-2 mRNA in SMCs with
doxycycline is mediated, at least in part, by decreasing
mRNA stability. Increased MMP expression in AAAs, es-
pecially MMP-2 and MMP-9, appears to be critical for
aortic dilation and AAA formation, and may also be pivotal
in atherosclerotic plaque rupture. Inasmuch as doxycycline
has an excellent safety profile for long-term use, with few
side effects,39 it could offer a therapeutic option for inhibi-
tion of growth of small AAAs. This will have to be evaluated
in carefully controlled clinical trials.
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